Skip to main content

About
Research and Development
- CPI-613^® (devimistat)
- CB-839 (telaglenastat)
Leadership
- Executive Management
- Board of Directors
Contact Us

News & Investors
- Press Releases

Clinical Trial Enrollment Contact Us

Investor/Media Kit

News & Investors

Press Releases

Investor/Media Kit Materials

Executive Management Bios
Cornerstone Pharma CPI-613 Factsheet
Cornerstone Pharma CB-839 Factsheet

info@cornerstonepharma.com

Cornerstone Pharmaceuticals, Inc. 9 Deerpark Drive, Suit J-5
Monmouth Junction, NJ 08852

Quick Links

Home
About
Research and Development
Leadership

© 2025 Cornerstone Pharmaceuticals, Inc. All Rights Reserved

Terms of Service
Privacy Policy
Terms of Use